Systemic Inflammatory Response Index (SIRI) at Baseline Predicts Clinical Response for a Subset of Treatment-Resistant Bipolar Depressed Patients
Journal of Personalized Medicine · 20.09.2023 · 13 (9) · 1408
DOI: 10.3390/jpm13091408 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 20.09.2023. Verfasst von Stephen Murata und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pine Rest Christian Mental Health Services, Michigan State University, 300 68th Street SE, Grand Rapids, MI 49548, USA. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stanley Foundation, Stanley Medical Research Institute (SMRI).
Abstract (Originalsprache)
Background: in a recent double-blind, placebo controlled RCT we demonstrated that selective inhibition of cyclo-oxygenase 2 (COX2) is an effective adjunctive strategy in treatment-resistant bipolar depression (TRBDD). To better clarify the mechanisms underlying TRBDD and treatment response, we conducted a retrospective exploratory analysis of the systemic inflammatory response index (SIRI = absolute neutrophils × absolute monocytes/absolute lymphocytes) in relation to other biomarkers and clinical outcomes after escitalopram (ESC), combined with the COX-2 inhibitor, celecoxib (CBX), versus placebo.
Methods
Baseline measures of SIRI were compared between TRBDD and healthy controls (HC), and correlated with blood-based inflammatory cytokines, kynurenines, and growth factors. Post-treatment Hamilton Depression Rating Scale 17 (HAMD-17) total scores (clinical outcome) were modelled according to SIRI adjusting for demographics (including relevant interactions with SIRI), baseline depression, treatment arm, and treatment timepoint using multiple linear regression and robust linear mixed effects models.
Results
Baseline SIRI did not distinguish TRBDD from HC groups. Baseline SIRI was significantly correlated with lower baseline MCP-1. The relationship between SIRI and HAMD-17 was significant at treatment week 8, in contrast to baseline. Finally, baseline SIRI predicted elevated post-treatment HAMD-17 scores, amongst patients with elevated depression scores at baseline. Significance: High pre-treatment SIRI may predict poorer depressive outcomes amongst TRBDD patients with baseline elevated depression.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pine Rest Christian Mental Health Services, Michigan State University, 300 68th Street SE, Grand Rapids, MI 49548, USA.
- Department of Psychiatry and Behavioral Neurosciences, Loyola University Chicago, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL 60153, USA.
- Stritch School of Medicine, Loyola University, Maywood, IL 60153, USA.
ORCID-Profile: Angelos Halaris
Förderung
- Stanley Foundation
- Stanley Medical Research Institute (SMRI)
Zitieren
APA
Murata, S., Baig, N., Decker, K., & Halaris, A. (2023). Systemic Inflammatory Response Index (SIRI) at Baseline Predicts Clinical Response for a Subset of Treatment-Resistant Bipolar Depressed Patients. Journal of Personalized Medicine, 13(9), 1408. https://doi.org/10.3390/jpm13091408
Vancouver
Murata S, Baig N, Decker K, Halaris A. Systemic Inflammatory Response Index (SIRI) at Baseline Predicts Clinical Response for a Subset of Treatment-Resistant Bipolar Depressed Patients. Journal of Personalized Medicine. 2023;13(9):1408. doi:10.3390/jpm13091408
BibTeX
@article{Murata2023,
author = {Murata, Stephen and Baig, Nausheen and Decker, Kyle and Halaris, Angelos},
title = {Systemic Inflammatory Response Index (SIRI) at Baseline Predicts Clinical Response for a Subset of Treatment-Resistant Bipolar Depressed Patients},
journal = {Journal of Personalized Medicine},
year = {2023},
volume = {13},
number = {9},
pages = {1408},
doi = {10.3390/jpm13091408}
}
EUVIMED